XULTIPHY Trademark

Trademark Overview

On Wednesday, June 19, 2013, a trademark application was filed for XULTIPHY with the United States Patent and Trademark Office. The USPTO has given the XULTIPHY trademark a serial number of 79136213. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Monday, June 19, 2023. This trademark is owned by Novo Nordisk A/S. The XULTIPHY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of diabetes
xultiphy

General Information

Serial Number79136213
Word MarkXULTIPHY
Filing DateWednesday, June 19, 2013
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateMonday, June 19, 2023
Registration Number4531442
Registration DateTuesday, May 20, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 4, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of diabetes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, February 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovo Nordisk A/S
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDK
Party NameNovo Nordisk A/S
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDK
Party NameNovo Nordisk A/S
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDK

Trademark Events

Event DateEvent Description
Friday, January 12, 2024NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Friday, January 12, 2024DEATH OF INTERNATIONAL REGISTRATION
Sunday, April 17, 2022TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, March 9, 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Wednesday, March 9, 2022INVALIDATION PROCESSED
Tuesday, October 26, 2021TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, February 26, 2021CANCELLED SECTION 71
Monday, May 20, 2019COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 17, 2014FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 2, 2014FINAL DISPOSITION NOTICE SENT TO IB
Thursday, October 2, 2014FINAL DISPOSITION PROCESSED
Wednesday, August 20, 2014FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, June 9, 2014ASSIGNED TO EXAMINER
Tuesday, May 20, 2014REGISTERED-PRINCIPAL REGISTER
Thursday, May 1, 2014NOTIFICATION PROCESSED BY IB
Thursday, April 10, 2014ASSIGNED TO EXAMINER
Tuesday, March 4, 2014PUBLISHED FOR OPPOSITION
Wednesday, February 12, 2014NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 12, 2014NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, February 12, 2014NOTICE OF PUBLICATION
Friday, January 24, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, January 24, 2014ASSIGNED TO LIE
Tuesday, December 31, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 31, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 30, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 30, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 21, 2013REFUSAL PROCESSED BY IB
Friday, October 4, 2013APPLICATION FILING RECEIPT MAILED
Tuesday, October 1, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, October 1, 2013REFUSAL PROCESSED BY MPU
Tuesday, October 1, 2013NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, September 30, 2013NON-FINAL ACTION WRITTEN
Monday, September 30, 2013ASSIGNED TO EXAMINER
Monday, September 30, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 27, 2013SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

xultiphy diabetes treatment preparations pharmaceutical